Results confirmed our suspicions that interfering with GDF15 would enhance response to eribulin: significantly increased cell death was seen when breast cancer cells were treated with the combination of anti-GDF15 antibody plus eribulin as compared to the combination using a nonspecific control IgG. This evidence concerns the gene GDF15 and breast cancer.